COMBINING PI3K, CDK4/6 PATHWAY INHIBITORS AND CHECKPOINT BLOCKADE IN TRIPLE-NEGATIVE BREAST CANCER
Grant number: 1123208 | Funding period: 2017 - 2019
Triple-negative breast cancer (TNBC) has the worst prognosis of all breast cancer subtypes, classically affecting young women and characterized by a lack of effective therapies. We show that blocking both PI3K and CDK4/6 pathways together effectively reduces TNBC growth in mice and can enhance anti-tumour immune responses. We aim to understand how these drugs work together and if adding immunotherapy can improve responses. Our project could provide a new treatment approach for TNBC patients.
Related publications (1)
Combined CDK4/6 and PI3K alpha Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
Zhi Ling Teo, Stephanie Versaci, Sathana Dushyanthen, Franco Caramia, Peter Savas, Chris P Mintoff, Magnus Zethoven, Balaji Virassamy, Stephen J Luen, Grant A McArthur, Wayne A Phillips, Phillip K Darcy, Sherene Loi